Low prevalence of methicillin resistant Staphylococcus aureus as determined by an automated identification system in two private hospitals in Nairobi, Kenya: a cross sectional study

BMC Infectious Diseases

Gunturu Revathi²  Beatrice Kabera¹  Geoffrey Omuse² 

[1] Gertrudes Children’s Hospital, Nairobi, Kenya;Aga Khan University Hospital Nairobi, Nairobi, Kenya

关键词: MRSA;    Antibiotic susceptibility;    Staphylococcus aureus;   

Others  :  1090835
DOI  :  10.1186/s12879-014-0669-y

 received in 2014-01-11, accepted in 2014-11-27,  发布年份 2014

【 摘 要 】

Background

Staphylococcus aureus (S.aureus) is a major cause of both healthcare and community acquired infections. In developing countries, manual phenotypic tests are the mainstay for the identification of staphylococci with the tube and slide coagulase tests being relied upon as confirmatory tests for S. aureus. The subjectivity associated with interpretation of these tests may result in misidentification of coagulase negative staphylococci as S.aureus. Given that antibiotic resistance is more prevalent in CONS, this may result in over estimation of methicillin resistant S.aureus (MRSA) prevalence.

Methods

A review of susceptibility data from all non-duplicate S.aureus isolates generated between March 2011 and May 2013 by the Vitek-2 (bioMérieux) automated system was performed by the authors. The data was generated routinely from processed clinical specimens submitted to the microbiology laboratories for culture and sensitivity at the Aga Khan University Hospital and Gertrude’s children’s hospital both situated in Nairobi.

Results

Antimicrobial susceptibility data from a total of 731 non-duplicate S.aureus isolates was reviewed. Majority (79.2%) of the isolates were from pus swabs. Only 24 isolates were both cefoxitin and oxacillin resistant while 3 were resistant to oxacillin but susceptible to cefoxitin giving an overall MRSA prevalence of 3.7% (27/731). None of the isolates were resistant to mupirocin, linezolid, tigecycline, teicoplanin or vancomycin.

Conclusion

The prevalence of MRSA in this study is much lower than what has been reported in most African countries. The significant change in antibiotic susceptibility compared to what has previously been reported in our hospital is most likely a consequence of the transition to an automated platform rather than a trend towards lower resistance rates.

【 授权许可】

   
2014 Omuse et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Fluit AC, Wielders CL, Verhoef J, Schmitz FJ: Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001, 39:3727-3732.
• [2]Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
• [3]McDonald LC: Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006, 42(Suppl 2):S65-S71.
• [4]Kesah C, Ben Redjeb S, Odugbemi TO, Boye CS, Dosso M, Ndinya Achola JO, Koulla-Shiro S, Benbachir M, Rahal K, Borg M: Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin Microbiol Infect 2003, 9:153-156.
• [5]Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmen E: The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005, 165:1756-1761.
• [6]Omari MA, Malonza IM, Bwayo JJ, Mutere AN, Murage EM, Mwatha AK, Ndinya-Achola JO: Pattern of bacterial infections and antimicrobial susceptibility at the Kenyatta National Hospital, Nairobi, Kenya. East Afr Med J 1997, 74:134-137.
• [7]Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H: Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 2004, 10:1627-1634.
• [8]Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP: MRSA in Africa: filling the global map of antimicrobial resistance. PLoS One 2013, 8:e68024.
• [9]Kohli R, Omuse G, Revathi G: Antibacterial susceptibility patterns of blood stream isolates in patients investigated at the Aga Khan University Hospital Nairobi. East Afr Med J 2010, 87:74-80.
• [10]Maina EK, Kiiyukia C, Wamae CN, Waiyaki PG, Kariuki S: Characterization of methicillin-resistant Staphylococcus aureus from skin and soft tissue infections in patients in Nairobi, Kenya. Int J Infect Dis 2012, 17:e115-e119.
• [11]Kateete DP, Kimani CN, Katabazi FA, Okeng A, Okee MS, Nanteza A, Joloba ML, Najjuka FC: Identification of Staphylococcus aureus: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test. Ann Clin Microbiol Antimicrob 2010, 9:23. BioMed Central Full Text
• [12]Sperber WH, Tatini SR: Interpretation of the tube coagulase test for identification of Staphylococcus aureus. Appl Microbiol 1975, 29:502-505.
• [13]Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillanc. Clin Infect Dis 2001, 32(Suppl 2):S114-S132.
• [14]Winstanley T, Courvalin P: Expert systems in clinical microbiology. Clin Microbiol Rev 2011, 24:515-556.
• [15]Spanu T, Sanguinetti M, Ciccaglione D, D’Inzeo T, Romano L, Leone F, Fadda G: Use of the VITEK 2 system for rapid identification of clinical isolates of Staphylococci from bloodstream infections. J Clin Microbiol 2003, 41:4259-4263.
• [16]CLSI: Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20, Vol. 29 No 3. Clinical Laboratory Standards Institute, Wayne, PA; 2010.
• [17]Omuse G, Kariuki S, Revathi G: Unexpected absence of meticillin-resistant Staphylococcus aureus nasal carriage by healthcare workers in a tertiary hospital in Kenya. J Hosp Infect 2012, 80:71-73.
• [18]Randrianirina F, Soares J-L, Ratsima E, Carod J-F, Combe P, Grosjean P, Richard V, Talarmin A: In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar. Ann Clin Microbiol Antimicrob 2007, 6:5. BioMed Central Full Text
• [19]Naik D, Teclu A: A study on antimicrobial susceptibility pattern in clinical isolates of Staphylococcus aureus in Eritrea. Pan Afr Med J 2009, 3:1.
• [20]Alabi AS, Frielinghaus L, Kaba H, Kösters K, Huson MA, Kahl BC, Peters G, Grobusch MP, Issifou S, Kremsner PG, Schaumburg F: Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa. BMC Infect Dis 2013, 13:455. BioMed Central Full Text
• [21]Chambers HF: Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997, 10:781-791.
• [22]Skinner S, Murray M, Walus T, Karlowsky JA: Failure of cloxacillin in treatment of a patient with borderline oxacillin-resistant Staphylococcus aureus endocarditis. J Clin Microbiol 2009, 47:859-861.
• [23]Buchan BW, Ledeboer NA: Identification of two borderline oxacillin-resistant strains of Staphylococcus aureus from routine nares swab specimens by one of three chromogenic agars evaluated for the detection of MRSA. Am J Clin Pathol 2010, 134:921-927.
• [24]Brink A, Moolman J, da Silva MC, Botha M: Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa. S Afr Med J 2007, 97:273-279.
• [25]Egyir B, Guardabassi L, Sørum M, Nielsen SS, Kolekang A, Frimpong E, Addo KK, Newman MJ, Larsen AR: Molecular Epidemiology and Antimicrobial Susceptibility of Clinical Staphylococcus aureus from Healthcare Institutions in Ghana. PLoS One 2014, 9:e89716.
• [26]Roberts S, Chambers S: Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J 2005, 35(Suppl 2):S97-S105.
• [27]Sabol KE, Echevarria KL, Lewis JS: Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother 2006, 40:1125-1133.
• [28]Drinkovic D: Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001, 48:315-316.
• [29]Marais E, Aithma N, Perovic O, Oosthuysen WF, Musenge E, Dusé AG: Antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus isolates from South Africa. S Afr Med J 2009, 99:170-173.
• [30]Salmenlinna S, Lyytikäinen O, Vuopio-Varkila J: Community-acquired methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis 2002, 8:602-607.